

# Allergic rhinitis - Pipeline Insight, 2021

<https://marketpublishers.com/r/A4FE183BD19BEN.html>

Date: June 2021

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: A4FE183BD19BEN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Allergic rhinitis - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Allergic rhinitis Understanding

#### Allergic rhinitis: Overview

Allergic rhinitis, or hay fever, is an allergic response to specific allergens. Common symptoms of allergic rhinitis include sneezing, runny nose, coughing, sore or scratchy throat, itchy eyes, watery eyes, dark circles under the eyes, frequent headaches, eczema-type symptoms, hives, and excessive fatigue. Allergic rhinitis is usually a long-standing condition that often goes undetected in the primary-care setting. A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis. Treatment of allergic rhinitis is symptomatic and depends on the type of allergen. Management includes medication like intranasal corticosteroids, antihistamines, decongestants, immunotherapy, eye drops and nasal sprays. Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of

treatment.

'Allergic rhinitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Allergic rhinitis pipeline landscape is provided which includes the disease overview and Allergic rhinitis treatment guidelines. The assessment part of the report embraces, in depth Allergic rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Allergic rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve Allergic rhinitis.

### Allergic rhinitis Emerging Drugs Chapters

This segment of the Allergic rhinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Allergic rhinitis Emerging Drugs

#### REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is a cocktail of three Bet v1 monoclonal antibodies. Regeneron Pharmaceuticals is investigating REGN5713-5714-5715 as intravenous injections in Phase III clinical studies for the treatment of allergic rhinitis and conjunctivitis.

#### Injectable MPL allergy vaccine: Allergy Therapeutics

Injectable MPL allergy vaccine is a subcutaneously administered vaccine containing glutaraldehyde-modified allergens and the adjuvants 3-deacylated monophosphoryl lipid A (MPL) and L-tyrosine. The drug is in Phase II/III clinical developmental studies for the treatment of Seasonal allergic rhinitis.

Further product details are provided in the report..

Allergic rhinitis: Therapeutic Assessment

This segment of the report provides insights about the different Allergic rhinitis drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Allergic rhinitis

There are approx. 35+ key companies which are developing the therapies for Allergic rhinitis. The companies which have their Allergic rhinitis drug candidates in the most advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals.

#### Phases

DelveInsight's report covers around 35+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Allergic rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs

by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Allergic rhinitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Allergic rhinitis therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Allergic rhinitis drugs.

## Allergic rhinitis Report Insights

Allergic rhinitis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Allergic rhinitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Allergic rhinitis drugs?

How many Allergic rhinitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Allergic rhinitis?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Allergic rhinitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Allergic rhinitis and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Abdi Ibrahim Pharmaceuticals

Allergy Therapeutics

Regeneron Pharmaceuticals

Laboratorios LETI

ALK-Abello

Advagene Biopharma

CSPC ZhongQi Pharmaceutical Technology

Array BioPharma

Immunotek

## Key Products

AI-201901

Injectable MPL allergy vaccine

REGN5713-5714-5715

House dust mite allergy immunotherapy

Birch pollen allergy vaccine tablet

B 244

AD 17002

CSPCHA-115

VTX-1463

MM09-MG01

MG 01/T 517

## Contents

- Introduction
- Executive Summary
- Allergic rhinitis: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Allergic rhinitis – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
  - Allergic rhinitis companies' collaborations, Licensing, Acquisition -Deal Value Trends
- Allergic rhinitis Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- REGN5713-5714-5715: Regeneron Pharmaceuticals
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report..
- Mid Stage Products (Phase II/III)
  - Comparative Analysis
- Injectable MPL allergy vaccine: Allergy Therapeutics
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report..



## Early Stage Products (Phase I/II)

- Comparative Analysis

### B 244: AOBiome

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report..

## Preclinical/Discovery Stage Products

- Comparative Analysis

### MM09-MG01: Immunotek

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report..

## Inactive Products

- Comparative Analysis

## Allergic rhinitis Key Companies

## Allergic rhinitis Key Products

## Allergic rhinitis- Unmet Needs

## Allergic rhinitis- Market Drivers and Barriers

## Allergic rhinitis- Future Perspectives and Conclusion

## Allergic rhinitis Analyst Views

## Allergic rhinitis Key Companies

## Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Allergic rhinitis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Allergic rhinitis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Allergic rhinitis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A4FE183BD19BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4FE183BD19BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970